16-30 of 388
Avery H. LaChance, MD, MPH, FAAD
Measuring What Matters in Psoriatic Arthritis
Living RheumMeasuring What Matters in Psoriatic Arthritis
Laura Coates, MBChB, MRCP, PhD
A Practical Guide to Chronic Spontaneous Urticaria
On the Frontlines of Chronic Spontaneous UrticariaA Practical Guide to Chronic Spontaneous Urticaria
Ryan Quigley
Jonathan Berstein, MD
Minimal Disease Activity: A Practical Target in Psoriatic Arthritis
Living RheumMinimal Disease Activity: A Practical Target in Psoriatic Arthritis
Laura Coates, MBChB, MRCP, PhD
Aligning Patient and Physician Perspectives in Psoriatic Arthritis
Living RheumAligning Patient and Physician Perspectives in Psoriatic Arthritis
Laura Coates, MBChB, MRCP, PhD
The Next Era of Psoriatic Arthritis Management
Living RheumThe Next Era of Psoriatic Arthritis Management
Laura Coates, MBChB, MRCP, PhD
- advertisement
Recognizing Neuroimmune Drivers of Itch in Atopic Dermatitis and Prurigo Nodularis
DermConsultRecognizing Neuroimmune Drivers of Itch in Atopic Dermatitis and Prurigo Nodularis
Steve Jackson, PharmD
Diego Ruiz Dasilva, MD, FAAD
Teledermatology Enables Earlier Diagnosis of Cutaneous Squamous Cell Carcinoma
Project Oncology®Teledermatology Enables Earlier Diagnosis of Cutaneous Squamous Cell Carcinoma
Smoking Status Predicts Worse Survival in Non-Melanoma Skin Cancer
Project Oncology®Smoking Status Predicts Worse Survival in Non-Melanoma Skin Cancer
Early Onset of Response to Zasocitinib (TAK-279), a Highly Selective and Potent TYK2 Inhibitor, Is Correlated With Modulation of TYK2 Signaling and Disease Pathway Biomarkers in Patients With Moderate-to-Severe Plaque Psoriasis
DermatologyEarly Onset of Response to Zasocitinib (TAK-279), a Highly Selective and Potent TYK2 Inhibitor, Is Correlated With Modulation of TYK2 Signaling and Disease Pathway Biomarkers in Patients With Moderate-to-Severe Plaque Psoriasis
April W. Armstrong, MD, MPH
Once-Daily Oral Zasocitinib Demonstrates Rapid and Reproducible Skin Clearance with a Consistent Safety Profile in Moderate-to-Severe Plaque Psoriasis: Results from Two Randomized Phase 3 Trials (LATITUDE-PsO-3001 and 3002)
DermatologyOnce-Daily Oral Zasocitinib Demonstrates Rapid and Reproducible Skin Clearance with a Consistent Safety Profile in Moderate-to-Severe Plaque Psoriasis: Results from Two Randomized Phase 3 Trials (LATITUDE-PsO-3001 and 3002)
Melinda Gooderham, MSc, MD, FRCPC
Unpacking the Complexity of Psoriatic Arthritis
Living RheumUnpacking the Complexity of Psoriatic Arthritis
Lawrence H. Brent
- advertisement
Diagnosing Psoriatic Arthritis: A Real-World Case
Living RheumDiagnosing Psoriatic Arthritis: A Real-World Case
Lawrence H. Brent
Modern Approaches to Psoriatic Arthritis Management
Living RheumModern Approaches to Psoriatic Arthritis Management
Lawrence H. Brent
Comparing Photodynamic Therapy Approaches in Basal Cell Carcinoma
AudioAbstractsComparing Photodynamic Therapy Approaches in Basal Cell Carcinoma
Ryan Quigley
